The Tumor Suppressor p53 and Histone Deacetylase 1 Are Antagonistic Regulators of the Cyclin-Dependent Kinase Inhibitor p21/WAF1/CIP1 Gene

REFERENCES

• Adamczewski, J. P., J. V. Gannon, and T. Hunt. 1993. Simian virus 40 large T antigen associates with cyclin A and p33cdk2. J. Virol. 67: 6551–6557.
   PubMedGoogle Scholar
• Archer, S. Y., S. Meng, A. Shei, and R. A. Hodin. 1998. p21(Waf1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 95: 6791–6796.
   PubMed Web of Science ®Google Scholar
• Ard, P. G., C. Chatterjee, S. Kunjibettu, L. R. Adside, L. E. Gralinski, and S. B. McMahon. 2002. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol. Cell. Biol. 22: 5650–5661.
   PubMed Web of Science ®Google Scholar
• Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and K. Kelly. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175–1184.
   PubMed Web of Science ®Google Scholar
• Bargonetti, J., and J. J. Manfredi. 2002. Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14: 86–91.
   PubMed Web of Science ®Google Scholar
• Barlev, N. A., L. Liu, N. H. Chehab, K. Mansfield, K. G. Harris, T. D. Halazonetis, and S. L. Berger. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8: 1243–1254.
   PubMed Web of Science ®Google Scholar
• Bartl, S., J. Taplick, G. Lagger, H. Khier, K. Kuchler, and C. Seiser. 1997. Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol. Cell. Biol. 17: 5033–5043.
   PubMed Web of Science ®Google Scholar
• Borellini, F., and R. I. Glazer. 1993. Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J. Biol. Chem. 268: 7923–7928.
   PubMedGoogle Scholar
• Braun, H., R. Koop, A. Ertmer, S. Nacht, and G. Suske. 2001. Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res. 29: 4994–5000.
   PubMed Web of Science ®Google Scholar
• Chuang, L. S., H. I. Ian, T. W. Koh, H. H. Ng, G. Xu, and B. F. Li. 1997. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 277: 1996–2000.
   PubMed Web of Science ®Google Scholar
• Doetzlhofer, A., H. Rotheneder, G. Lagger, M. Koranda, V. Kurtev, G. Brosch, E. Wintersberger, and C. Seiser. 1999. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol. Cell. Biol. 19: 5504–5511.
   PubMed Web of Science ®Google Scholar
• el-Deiry, W. S. 1998. Regulation of p53 downstream genes. Semin. Cancer Biol. 8: 345–357.
   PubMed Web of Science ®Google Scholar
• el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
   PubMed Web of Science ®Google Scholar
• Espinosa, J. M., and B. M. Emerson. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8: 57–69.
   PubMed Web of Science ®Google Scholar
• Gartel, A. L., E. Goufman, F. Najmabadi, and A. L. Tyner. 2000. Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line. Oncogene 19: 5182–5188.
   PubMedGoogle Scholar
• Gartel, A. L., and A. L. Tyner. 1999. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp. Cell Res. 246: 280–289.
   PubMed Web of Science ®Google Scholar
• Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595–606.
   PubMed Web of Science ®Google Scholar
• Gu, W., X. L. Shi, and R. G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature 387: 819–823.
   PubMed Web of Science ®Google Scholar
• Gualberto, A., and A. S. Baldwin, Jr. 1995. p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J. Biol. Chem. 270: 19680–19683.
   PubMedGoogle Scholar
• Hagen, G., S. Muller, M. Beato, and G. Suske. 1994. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J. 13: 3843–3851.
   PubMedGoogle Scholar
• Han, J. W., S. H. Ahn, Y. K. Kim, G. U. Bae, J. W. Yoon, S. Hong, H. Y. Lee, Y. W. Lee, and H. W. Lee. 2001. Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J. Biol. Chem. 276: 42084–42090.
   PubMedGoogle Scholar
• Han, J. W., S. H. Ahn, S. H. Park, S. Y. Wang, G. U. Bae, D. W. Seo, H. K. Kwon, S. Hong, H. Y. Lee, Y. W. Lee, and H. W. Lee. 2000. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60: 6068–6074.
   PubMed Web of Science ®Google Scholar
• Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816.
   PubMed Web of Science ®Google Scholar
• Huang, L., Y. Sowa, T. Sakai, and A. B. Pardee. 2000. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19: 5712–5719.
   PubMed Web of Science ®Google Scholar
• Hubbert, C., A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, X. F. Wang, and T. P. Yao. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417: 455–458.
   PubMed Web of Science ®Google Scholar
• Ito, A., Y. Kawaguchi, C. H. Lai, J. J. Kovacs, Y. Higashimoto, E. Appella, and T. P. Yao. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21: 6236–6245.
   PubMed Web of Science ®Google Scholar
• Ito, A., C. H. Lai, X. Zhao, S. Saito, M. H. Hamilton, E. Appella, and T. P. Yao. 2001. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20: 1331–1340.
   PubMed Web of Science ®Google Scholar
• Juan, L. J., W. J. Shia, M. H. Chen, W. M. Yang, E. Seto, Y. S. Lin, and C. W. Wu. 2000. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275: 20436–20443.
   PubMed Web of Science ®Google Scholar
• Kaeser, M. D., and R. D. Iggo. 2002. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99: 95–100.
   PubMed Web of Science ®Google Scholar
• Karlseder, J., H. Rotheneder, and E. Wintersberger. 1996. Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F. Mol. Cell. Biol. 16: 1659–1667.
   PubMed Web of Science ®Google Scholar
• Khochbin, S., and H. Y. Kao. 2001. Histone deacetylase complexes: functional entities or molecular reservoirs. FEBS Lett. 494: 141–144.
   PubMedGoogle Scholar
• Kim, Y. B., K. H. Lee, K. Sugita, M. Yoshida, and S. Horinouchi. 1999. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18: 2461–2470.
   PubMed Web of Science ®Google Scholar
• Koutsodontis, G., I. Tentes, P. Papakosta, A. Moustakas, and D. Kardassis. 2001. Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein. J. Biol. Chem. 276: 29116–29125.
   PubMedGoogle Scholar
• Kouzarides, T. 2000. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19: 1176–1179.
   PubMed Web of Science ®Google Scholar
• Kramer, O. H., M. Gottlicher, and T. Heinzel. 2001. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12: 294–300.
   PubMed Web of Science ®Google Scholar
• Lagger, G., D. O'Carroll, M. Rembold, H. Khier, J. Tischler, G. Weitzer, B. Schuettengruber, C. Hauser, R. Brunmeir, T. Jenuwein, and C. Seiser. 2002. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21: 2672–2681.
   PubMed Web of Science ®Google Scholar
• Langley, E., M. Pearson, M. Faretta, U. M. Bauer, R. A. Frye, S. Minucci, P. G. Pelicci, and T. Kouzarides. 2002. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21: 2383–2396.
   PubMed Web of Science ®Google Scholar
• Lechner, T., A. Lusser, G. Brosch, A. Eberharter, M. Goralik Schramel, and P. Loidl. 1996. A comparative study of histone deacetylases of plant, fungal and vertebrate cells. Biochim. Biophys. Acta 1296: 181–188.
   PubMedGoogle Scholar
• Liu, L., D. M. Scolnick, R. C. Trievel, H. B. Zhang, R. Marmorstein, T. D. Halazonetis, and S. L. Berger. 1999. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19: 1202–1209.
   PubMed Web of Science ®Google Scholar
• Luo, J., A. Y. Nikolaev, S.-I. Imai, A. Shiloh, L. Guarente, and W. Gu. 2001. Negative control of p53 by Sir2′ promotes cell survival under stress. Cell 107: 137–148.
   PubMed Web of Science ®Google Scholar
• Luo, J., F. Su, D. Chen, A. Shiloh, and W. Gu. 2000. Deacetylation of p53α modulates its effect on cell growth and apoptosis. Nature 408: 377–381.
   PubMed Web of Science ®Google Scholar
• Maehara, K., N. Uekawa, and K. Isobe. 2002. Effects of histone acetylation on transcriptional regulation of manganese superoxide dismutase gene. Biochem. Biophys. Res. Commun. 295: 187–192.
   PubMedGoogle Scholar
• Marks, P. A., R. A. Rifkind, V. M. Richon, and R. Breslow. 2001. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res. 7: 759–760.
   PubMed Web of Science ®Google Scholar
• Murphy, M., J. Ahn, K. K. Walker, W. H. Hoffman, R. M. Evans, A. J. Levine, and D. L. George. 1999. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13: 2490–2501.
   PubMed Web of Science ®Google Scholar
• Nakamura, S., J. A. Roth, and T. Mukhopadhyay. 2000. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol. Cell. Biol. 20: 9391–9398.
   PubMedGoogle Scholar
• Nakano, K., T. Mizuno, Y. Sowa, T. Orita, T. Yoshino, Y. Okuyama, T. Fujita, N. Ohtani Fujita, Y. Matsukawa, T. Tokino, H. Yamagishi, T. Oka, H. Nomura, and T. Sakai. 1997. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem. 272: 22199–22206.
   PubMed Web of Science ®Google Scholar
• Noda, A., Y. Ning, S. F. Venable, O. M. Pereira-Smith, and J. R. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211: 90–98.
   PubMed Web of Science ®Google Scholar
• Ohlsson, C., N. Kley, H. Werner, and D. LeRoith. 1998. p53 regulates insulin-like growth factor-I (Igf-I) receptor expression and Igf-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139: 1101–1107.
   PubMed Web of Science ®Google Scholar
• Oren, M. 1999. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274: 36031–36034.
   PubMed Web of Science ®Google Scholar
• Prives, C., and J. L. Manley. 2001. Why is p53 acetylated? Cell 107: 815–818.
   PubMed Web of Science ®Google Scholar
• Richon, V. M., S. Emiliani, E. Verdin, Y. Webb, R. Breslow, R. A. Rifkind, and P. A. Marks. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 95: 3003–3007.
   PubMed Web of Science ®Google Scholar
• Saito, A., T. Yamashita, Y. Mariko, Y. Nosaka, K. Tsuchiya, T. Ando, T. Suzuki, T. Tsuruo, and O. Nakanishi. 1999. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96: 4592–4597.
   PubMed Web of Science ®Google Scholar
• Sakaguchi, K., J. E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C. W. Anderson, and E. Appella. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12: 2831–2841.
   PubMed Web of Science ®Google Scholar
• Sambucetti, L. C., D. D. Fischer, S. Zabludoff, P. O. Kwon, H. Chamberlin, N. Trogani, H. Xu, and D. Cohen. 1999. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274: 34940–34947.
   PubMed Web of Science ®Google Scholar
• Scolnick, D. M., N. H. Chehab, E. S. Stavridi, M. C. Lien, L. Caruso, E. Moran, S. L. Berger, and T. D. Halazonetis. 1997. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 57: 3693–3696.
   PubMed Web of Science ®Google Scholar
• Sowa, Y., T. Orita, S. Minamikawa, K. Nakano, T. Mizuno, H. Nomura, and T. Sakai. 1997. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241: 142–150.
   PubMed Web of Science ®Google Scholar
• Sowa, Y., T. Orita, S. Minamikawa-Hiranabe, T. Mizuno, H. Nomura, and T. Sakai. 1999. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res. 59: 4266–4270.
   PubMed Web of Science ®Google Scholar
• Sun, J. M., H. Y. Chen, M. Moniwa, D. W. Litchfield, E. Seto, and J. R. Davie. 2002. The transcriptional repressor Sp3 is associated with CK2 phosphorylated histone deacetylase 2. J. Biol. Chem. 277: 35783–35786.
   PubMedGoogle Scholar
• Suske, G. 1999. The Sp-family of transcription factors. Gene 238: 291–300.
   PubMed Web of Science ®Google Scholar
• Torgeman, A., N. Mor-Vaknin, E. Zelin, Z. Ben-Aroya, M. Lochelt, R. M. Flugel, and M. Aboud. 2001. Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. Virology 281: 10–20.
   PubMedGoogle Scholar
• Van Lint, C., S. Emiliani, and E. Verdin. 1996. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5: 245–253.
   PubMed Web of Science ®Google Scholar
• Vaziri, H., S. K. Dessain, E. Ng Eaton, S. I. Imai, R. A. Frye, T. K. Pandita, L. Guarente, and R. A. Weinberg. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149–159.
   PubMed Web of Science ®Google Scholar
• Won, J., J. Yim, and T. K. Kim. 2002. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J. Biol. Chem. 277: 38230–38238.
   PubMedGoogle Scholar
• Xiao, H., T. Hasegawa, and K. Isobe. 1999. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem. 73: 291–302.
   PubMed Web of Science ®Google Scholar
• Xiao, H., T. Hasegawa, and K. Isobe. 2000. p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J. Biol. Chem. 275: 1371–1376.
   PubMedGoogle Scholar
• Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., and M. L. Dufau. 2002. Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex. J. Biol. Chem. 277: 33431–33438.
   PubMedGoogle Scholar